Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019
BURLINGTON, Mass. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Thursday, February 28, 2019 .
View HTML
Toggle Summary Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Rheumatology and Therapy
Results from Phase 3b clinical trial indicate that repeat administration of ZILRETTA for osteoarthritis (OA) knee pain was generally safe and well-tolerated X-ray data at baseline and Week 52 showed ZILRETTA had no deleterious impact on cartilage or joint structure     The majority (74%) of
View HTML
Toggle Summary Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12
BURLINGTON, Mass. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has been invited to ring the Nasdaq opening bell on Tuesday, February 12, 2019 to commemorate the fifth anniversary of the company’s initial public offering (IPO).
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Feb. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to 14 new employees for an aggregate of 51,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an
View HTML
Toggle Summary Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer
BURLINGTON, Mass. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Christina Willwerth has been named Chief Strategy Officer. Ms. Willwerth joined Flexion in June 2009 , and she most recently served as the company’s Senior Vice President of Program
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 53,700 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019
Fourth-quarter 2018 revenue estimated to be approximately $9.5 million , an increase of 36% over the previous quarter Full-year 2018 revenue estimated to be approximately $22.5 million Flexion providing initial 2019 product revenue guidance of $65 to $80 million Conference call scheduled for
View HTML
Toggle Summary Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study
First patient enrolled in Phase 3 hip OA registration trial in late December 2018 ; trial expected to complete in 2020 Positive results from Phase 2 pharmacokinetics (PK) study of ZILRETTA in OA of shoulder and hip showed PK profiles consistent with previous studies in knee Additional Phase 2
View HTML
Toggle Summary Flexion Therapeutics to Report Preliminary Unaudited 2018 Revenue and Provide 2019 Revenue Guidance on January 3, 2019
BURLINGTON, Mass. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will announce preliminary unaudited revenue for the fourth-quarter and full-year 2018 and provide revenue guidance for 2019 on Thursday, January 3, 2019 , after market close.
View HTML
Toggle Summary Flexion Therapeutics Submits Supplemental New Drug Application (sNDA) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
sNDA aims to revise the product label with new data indicating repeat administration of ZILRETTA was safe and well tolerated BURLINGTON, Mass. , Dec. 17, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced it submitted a supplemental new drug application (sNDA) to the
View HTML